PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.4800
+0.1200 (+5.08%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.3600
Open2.4300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.3600 - 2.5000
52 Week Range0.6000 - 4.4900
Volume10,163
Avg. Volume16,242
Market Cap6.87M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.
    PR Newswire

    Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its pending merger partner Cannaworx, Inc. will be launching its patented and proprietary immune booster supplement by mid-July 2020. The Company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim.

  • Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution Network
    PR Newswire

    Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution Network

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that one of their two pending merger partners – Cannaworx, Inc. - is significantly expanding their sales and distribution network with an agreement to acquire Louisiana-based Five Leaf Labs ("FLL"). This expansion of their sales and distribution network comes at a critical time for Cannaworx, as they are anticipating the market launch of their first two products over the coming few weeks.

  • Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners
    PR Newswire

    Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that following its previously announced pending merger (Click Here) and name change to Availa Bio, that the newly branded, publicly-traded company will be entering the hand sanitizer market through the founders of Cannaworx. The custom-designed, next generation, premium hand sanitizer will be the first product released under the new holding company Availa Bio.

  • Former L'Oréal President Jim Morrison Appointed as CEO To Lead Availa Bio Upon Merger of Pressure BioSciences, Cannaworx and SkinScience Labs
    PR Newswire

    Former L'Oréal President Jim Morrison Appointed as CEO To Lead Availa Bio Upon Merger of Pressure BioSciences, Cannaworx and SkinScience Labs

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), today announced that personal care industry leader Jim Morrison has been appointed to serve as the new CEO of the rebranded public company, Availa Bio, upon completion of the merger with Cannaworx, SkinScience Labs and Pressure BioSciences. As part of the proposed transactions, the Company intends to change the corporation's name to Availa Bio. Morrison has had a legendary career including numerous leadership positions in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure.

  • Pressure BioSciences Announces Planned Name Change to "Availa Bio" Following Completion of Cannaworx and SkinScience Labs Transactions
    PR Newswire

    Pressure BioSciences Announces Planned Name Change to "Availa Bio" Following Completion of Cannaworx and SkinScience Labs Transactions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced its intention to change the corporation's name to Availa Bio upon completion of the acquisitions and merger of Cannaworx, Inc. and SkinScience Labs, Inc. with PBI. The three companies will operate as synergistic divisions within the combined "Availa Bio" entity. This strategic change in corporate identity and branding reflects the science-driven collaboration of the companies focused on the overarching priority of leveraging the revolutionary Ultra Shear Technology™(UST™) platform to bring significant new value to consumers in optimized bioavailability, absorption, quality and performance across Availa Bio's diverse range of human, animal and agricultural products being introduced in the coming months or already on market.

  • Pressure BioSciences' Recently Announced Acquisitions Advance the Company Forward
    Newsfile

    Pressure BioSciences' Recently Announced Acquisitions Advance the Company Forward

    New York, New York--(Newsfile Corp. - May 4, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was recently covered by leading publisher Small Caps Daily concerning their recently announced accretive acquisitions which position the Company to expand into several lucrative markets. ...

  • Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.
    PR Newswire

    Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced a letter of intent to acquire SkinScience Labs, Inc., parent company of the award-winning Dr. Denese skin care and anti-aging product lines. The rights to acquire SkinScience Labs, Inc., which includes Dr. Denese SkinScience, is through Cannaworx, Inc. PBI announced plans on April 28, 2020 to acquire Cannaworx, Inc. (Click here).

  • Pressure BioSciences Announces Plans to Acquire Cannaworx, Inc.
    PR Newswire

    Pressure BioSciences Announces Plans to Acquire Cannaworx, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that it has signed a binding letter of intent to merge with Cannaworx, Inc. (USA) and its diverse portfolio of products and intellectual property developed by its founders Bobby Ghalili, DMD and Adrienne Denese, MD, PhD.

  • Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics
    PR Newswire

    Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI's patented Pressure Cycling Technology ("PCT") with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS") resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS"). The Company believes combining both platforms enables the rigorous investigation of protein structure and stability in a streamlined and highly efficient workflow that can be critical in drug development.

  • Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions
    PR Newswire

    Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer, Can B Corp (OTC: CANBD), for one of its proprietary BaroShear K45 Ultra Shear Technology™ ("UST™")-based systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory
    PR Newswire

    Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™ ("UST™") Demonstration Laboratory (the "UST Demo Lab"). The UST Demo Lab is located in the Company's South Easton, Massachusetts facility.

  • Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.
    PR Newswire

    Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research ("Zacks SCR") has released an updated research report in its on-going coverage on the Company.

  • Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument
    PR Newswire

    Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D; scale, Ultra Shear Technology™ ("UST™")-based BaroShear instrument to the market in the third quarter of 2020. The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

  • Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil
    PR Newswire

    Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil

    Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer for six (6) proprietary Ultra Shear Technology™ ("UST™")-based nanoemulsification systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the bioavailability of today's macro or microemulsions of CBD Oil.

  • Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine
    Newsfile

    Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine

    Cannabis Brightline Article Highlights Potential of PBI's UST Platform to Play Significant Role in Multiple Billion Dollar Markets - Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage South Easton, Massachusetts--(Newsfile Corp. - January 17, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company's new ...

  • Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019
    Newsfile

    Number of Published Scientific Papers Citing the Advantages of Pressure BioSciences' PCT Platform Remained Strong in 2019

    For the Second Straight Year, Over 20 Journal Articles Highlight the Benefits of PBI's Patented PCT Platform in Such Critical Areas of Research as Cancer, Food Safety, and Proteomics South Easton, Massachusetts--(Newsfile Corp. - January 9, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in ...

  • GlobeNewswire

    Pressure BioSciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Significant Revenue Growth Reported in Consumable Products (158%) and Scientific Services (87%);Company Continues to Gain Momentum in Its PCT, BaroFold, and UST Technology.

  • GlobeNewswire

    Pressure BioSciences, Inc. to Discuss Third Quarter 2019 Financial Results and Provide Business Update

    SOUTH EASTON, Mass., Dec. 18, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a.

  • GlobeNewswire

    Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

    SOUTH EASTON, Mass., Oct. 04, 2019 -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly.

  • GlobeNewswire

    Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting

    SOUTH EASTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples.  This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.

  • ACCESSWIRE

    Pressure BioSciences Provides Corporate Update, Focus on CBD Market and Growth Drivers for 2019-2020 in New SNNLive Video Interview on StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Richard T. Schumacher, President and CEO of Pressure ...

  • GlobeNewswire

    Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference

    International HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease.  The multiple PCT-related presentations included development of new methods and applications using PBI’s unique PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery. Ms. Roxana McCloskey, PBI's Global Director of Sales & Marketing, commented: "We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles.

  • Newsfile

    Pressure BioSciences, Inc. Discusses Major Advancements Its PCT, BaroFold, and BaroShear K45 Platforms

    Phoenix, Arizona--(Newsfile Corp. - September 18, 2019) - The Stock Day Podcast recently welcomed Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ("the Company"), to discuss PBIO on Stock Day with its host Mr. Everett Jolley. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry.Mr. Jolly began the interview by welcoming Mr. Schumacher back to the ...

  • GlobeNewswire

    Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer 

    Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South.

  • GlobeNewswire

    Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics

    SOUTH EASTON, MA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of  scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers.  The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems.  The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.